.png){kind=small}
Our Science
Technology & Platform
Our innovative platform combines advanced cancer targeting agents, proprietary chelators, and therapeutic radioisotopes for precision oncology.
Targeted radiopharmaceutical therapy
Targeted radiopharmaceuticals typically involve three components, a cancer targeting agent (such as monoclonal antibodies, antibody fragments, peptides), a bifunctional chelator and a radioisotope. The cancer targeting agent specifically binds to cancer cells and delivers radioisotopes directly to cancer cells while minimizing exposure to normal tissues. The cancer site-specific accumulation of radioisotopes can either be used as contrast agents for diagnostic imaging or to deliver lethal dosage of radiation to kill cancer cells by inducing DNA damage and activating the immune system.
The attributes (stability and specificity) of each of these components play a significant role in determining specificity of accumulation of radiation in cancer versus normal tissues. ACT225 BioTx has developed proprietary cancer targeting moieties and bifunctional chelators for optimal uptake of radiation at cancer sites, while minimizing off target effects. ACT225BioTx’s lead drug candidates feature dual payloads for enhanced efficacy at killing resistant cancers, with improved safety profiles.
Antibody formats
IgG1
Full antibody
scFv
Single-chain variable fragment
Bispecific
Dual target binding
Fab
Fragment antigen-binding
Nanobody
Single-domain antibody
Tetrameric
Tetrameric
Engineered cancer targeting molecules
ACT225 BioTx has a robust antibody/protein engineering platform that generates cancer targeting biologics against cancer cell specific markers. Using combinatorial phage-displayed libraries, we typically select, screen and optimize binders for excellent stability, affinity and binding specificity.
ACT225 BioTx has generated several fully-human antibodies (IgG1) and antibody binding fragments (Fab, scFv and nanobodies) against various targets, which have been validated to have excellent biodistribution and pharmacokinetic (PK) properties when injected into mouse models of cancer.
The modular nature of the binders allows tailored incorporation into different antibody formats including bispecific and tetrameric antibodies, thereby enabling optimized and tailored biodistribution and PK properties.
Novel Chelators
ACT225 BioTx has engineered proprietary bifunctional chelators that can stably incorporate alpha- and beta- emitting radioisotopes when conjugated to our cancer targeting molecules. By using the same chelator for imaging and therapeutic isotopes, we can accurately project the quantitative imaging studies to determine the optimal patient dosage.
Alpha emitters (actinium-225)
High energy, short range radiation
Beta emitters (terbium-161)
High energy, short range radiation
Stable metal-chelate complex